Abstract

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema that has inadequately responded to previous therapy, in adults whose eyes have natural lenses (phakic eyes).

Is this guidance up to date?

Next review: 2022

Guidance development process

How we develop NICE technology appraisal guidance

This guidance partially updates NICE technology appraisal guidance 301 on fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy.